Achelios Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $11M
Latest Deal Amount
  • Investors
  • 3

Achelios Therapeutics General Information

Description

Developer of pharmaceutical products designed to reformulate non-steroidal anti-inflammatory drug molecules as topically delivered medications. The company's technology focuses on therapeutic compound development for the treatment of sprains, migraine prophylaxis, osteoarthritis, and strains by decreasing side effects and improving efficacy, thereby enabling patients to receive faster and improved pain relief.

Contact Information

Formerly Known As
Exodos life Sciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Primary Office
  • 4364 South Alston Avenue
  • Suite 300
  • Durham, NC 27713
  • United States
+1 (919) 000-0000

Achelios Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Achelios Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 01-Feb-2021 $11M 000.00 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A1) 01-Oct-2020 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
3. Debt - General 14-Apr-2020 00.000 00.000 Completed Clinical Trials - Phase 2
2. Seed Round 13-Mar-2014 $3.17M $5.17M 000.00 Completed Clinical Trials - Phase 1
1. Capitalization 02-Feb-2012 $2M $2M 000 Completed Pre-Clinical Trials
To view Achelios Therapeutics’s complete valuation and funding history, request access »

Achelios Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00.0 00 00 00 00 00.000
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view Achelios Therapeutics’s complete cap table history, request access »

Achelios Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pharmaceutical products designed to reformulate non-steroidal anti-inflammatory drug molecules as topically
Drug Delivery
Durham, NC
6 As of 2021
000.00
000 0000-00-00
00000000000 000.00

0000000

t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Oss, Netherlands
00 As of 0000
000.00
0000000000 0 000.00

00000 00

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000 000000000
Carlsbad, CA
000 As of 0000
0000
0.000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Achelios Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Citryll Venture Capital-Backed Oss, Netherlands 00 000.00 0000000000 0 000.00
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
You’re viewing 3 of 3 competitors. Get the full list »

Achelios Therapeutics Patents

Achelios Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170266106-A1 Methods and compositions for treating migraine and conditions associated with pain Abandoned 01-Dec-2014 0000000000
CA-3006962-A1 Methods and compositions for treating migraine and conditions associated with pain Pending 01-Dec-2014 0000000000
JP-2017536421-A Methods and compositions for treating conditions associated with migraine and pain Pending 01-Dec-2014 0000000000
JP-2020073563-A Methods and compositions for treating migraine and conditions associated with pain Granted 01-Dec-2014 0000000000
EP-3226972-A4 Methods and compositions for treating migraine and conditions associated with pain Pending 01-Dec-2014 A61K9/0014 0

Achelios Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Crist Frangakis Ph.D Founder, Chief Executive Officer, President & Board Member
Wade Ficken Chief Financial Officer
James Yeager Chief Technology Officer
Steve King Chief Development Officer
Mike Fox Chief Commercial Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Achelios Therapeutics Board Members (7)

Name Representing Role Since
Crist Frangakis Ph.D Achelios Therapeutics Founder, Chief Executive Officer, President & Board Member 000 0000
Jerry Rosenblatt Achelios Therapeutics Board Member 000 0000
Jon Saxe Achelios Therapeutics Board Member 000 0000
Michael Barthalomew Achelios Therapeutics Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

Achelios Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Achelios Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jon Gurman Angel (individual) Minority 000 0000 000000 0
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
Kyto Technology And Life Science Corporation Minority 000 0000 000000 0
To view Achelios Therapeutics’s complete investors history, request access »